title: Ticagrelor: a novel drug for an old problem.
abstract: Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes of death in the industrialized countries. In the setting of acute coronary syndromes (both ST - segment or non ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development. Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting atherothrombotic disease. Recent patent relates to the methods and devices for treating atherosclerosis and to prevent in-stent restenosis or thrombosis. Because of the importance of platelets involvement in the initiation and propagation of thrombosis, antiplatelet drugs have a source of research; in the recent past, new antiplatelet drugs (such as ticagrelor) have been studied and placed in the routine therapy. The aim of this paper is to summarize the pharmacological properties and the clinical characteristics of ticagrelor.
authors.forename: Andrea
authors.initials: A
authors.lastname: Rognoni
authors.forename: Chiara
authors.initials: C
authors.lastname: Cavallino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lupi
authors.forename: Gioel G
authors.initials: GG
authors.lastname: Secco
authors.forename: Alessia
authors.initials: A
authors.lastname: Veia
authors.forename: Sara
authors.initials: S
authors.lastname: Bacchini
authors.forename: Roberta
authors.initials: R
authors.lastname: Rosso
authors.forename: Sandra
authors.initials: S
authors.lastname: Brunelleschi
authors.forename: Francesco
authors.initials: F
authors.lastname: Rametta
authors.affiliation: Coronary Care Unit and Catheterization Laboratory, "Maggiore della Carità" Hospital, Corso Mazzini 18, 28100 Novara, Italy. arognoni@hotmail.com.
authors.forename: Angelo S
authors.initials: AS
authors.lastname: Bongo
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D010330:Patents as Topic; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy / Q000473:pathology; D000077486:Ticagrelor
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine